This HTML5 document contains 49 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n7http://linked.opendata.cz/resource/domain/vavai/subjekt/
n6http://linked.opendata.cz/ontology/domain/vavai/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00179906%3A_____%2F11%3A10110344%21RIV12-MZ0-00179906/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n8http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n10http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00179906%3A_____%2F11%3A10110344%21RIV12-MZ0-00179906
rdf:type
n6:Vysledek skos:Concept
rdfs:seeAlso
http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2010.09707.x/pdf
dcterms:description
To retrospectively evaluate the effect of subsequent tyrosine kinase inhibitors (TKIs) after first-line bevacizumab + interferon-alfa2a (IFN) or IFN + placebo in the phase III AVOREN (Avastin and Roferon in Renal Cell Carcinoma) trial. Multiple active treatment options are available for patients with mRCC. Current data suggest that it is difficult to use these therapies in combination due to toxicity concerns. The ability to use these active therapies sequentially provides the potential for improved patient outcomes. To retrospectively evaluate the effect of subsequent tyrosine kinase inhibitors (TKIs) after first-line bevacizumab + interferon-alfa2a (IFN) or IFN + placebo in the phase III AVOREN (Avastin and Roferon in Renal Cell Carcinoma) trial. Multiple active treatment options are available for patients with mRCC. Current data suggest that it is difficult to use these therapies in combination due to toxicity concerns. The ability to use these active therapies sequentially provides the potential for improved patient outcomes.
dcterms:title
Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial
skos:prefLabel
Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-alpha 2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial
skos:notation
RIV/00179906:_____/11:10110344!RIV12-MZ0-00179906
n6:predkladatel
n7:ico%3A00179906
n3:aktivita
n19:S n19:N
n3:aktivity
N, S
n3:cisloPeriodika
2
n3:dodaniDat
n10:2012
n3:domaciTvurceVysledku
n13:5290791
n3:druhVysledku
n18:J
n3:duvernostUdaju
n14:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
219160
n3:idVysledku
RIV/00179906:_____/11:10110344
n3:jazykVysledku
n4:eng
n3:klicovaSlova
tyrosine kinase inhibitors; sequencing; overall survival; metastatic RCC; bevacizumab
n3:klicoveSlovo
n5:overall%20survival n5:tyrosine%20kinase%20inhibitors n5:metastatic%20RCC n5:bevacizumab n5:sequencing
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[ACDFEF01413B]
n3:nazevZdroje
BJU International
n3:obor
n11:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
8
n3:rokUplatneniVysledku
n10:2011
n3:svazekPeriodika
107
n3:tvurceVysledku
Sneller, Vesna Bellmunt, Joaquim Bracarda, Sergio Bajetta, Emilio Négrier, Sylvie Escudier, Bernard Ravaud, Alain Melichar, Bohuslav
n3:wos
000285922200005
s:issn
1464-4096
s:numberOfPages
6
n8:doi
10.1111/j.1464-410X.2010.09707.x